Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 5/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.34 |
| ▸ | IDH1 | O75874 | 4/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12092438 | 1.00 | CYP19A1 (0.40) | CYP19A1DRD2DRD3GRIN1GRIN2B | |
| SCHEMBL12092459 | 1.00 | CYP19A1 (0.40) | CYP19A1DRD2DRD3GRIN1GRIN2B | |
| Hydrochloric Acid SCHEMBL1757938 | 0.99 | CYP19A1 (0.39) | CYP19A1DRD2DRD3GRIN1GRIN2B | |
| SCHEMBL1338025 | 0.91 | DRD2 (0.43) | CYP19A1DRD2DRD3GRIN1GRIN2B | |
| SCHEMBL337755 | 0.83 | CYP19A1 (0.54) | CYP19A1GRIN2B | |
| SCHEMBL346472 | 0.83 | CYP19A1 (0.54) | CYP19A1GRIN2B | |
| SCHEMBL1339080 | 0.83 | CYP19A1 (0.54) | CYP19A1GRIN2B | |
| SCHEMBL4053243 | 0.79 | DRD2 (0.33) | CYP19A1DRD2 | |
| SCHEMBL348914 | 0.77 | CYP19A1 (0.47) | CYP19A1GRIN2B | |
| SCHEMBL7799472 | 0.76 | CYP19A1 (0.46) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 127 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3763370-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE | ALLERGAN, INC. (US) | 2021-01-13 | — | — | EP | claimed |
| EP-3184110-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE | ALLERGAN INC (US) | 2020-10-07 | — | — | EP | claimed |
| US-10201535-B2 | Pharmaceutical compositions comprising 7-(1H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | ALLERGAN, INC. (US) | 2019-02-12 | — | — | US | claimed |
| US-20170182028-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. | 2017-06-29 | — | — | US | claimed |
| EP-3184110-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE | ALLERGAN, INC. (US) | 2017-06-28 | — | — | EP | claimed |
| US-20170095466-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. | 2017-04-06 | — | — | US | claimed |
| EP-2776034-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (S)-(+)-7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN INC (US) | 2017-03-22 | — | — | EP | claimed |
| US-20160151349-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. | 2016-06-02 | — | — | US | claimed |
| US-9283217-B2 | Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | ALLERGAN, INC. (US) | 2016-03-15 | — | — | US | claimed |
| US-20160051534-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8- TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. | 2016-02-25 | — | — | US | claimed |
| US-20150231128-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. | 2015-08-20 | — | — | US | claimed |
| EP-2785345-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR RETINAL NEUROPROTECTION | ALLERGAN, INC. (US) | 2014-10-08 | — | — | EP | claimed |
| EP-2776034-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| US-20130203809-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. (US) | 2013-08-08 | — | — | US | claimed |
| WO-2013081981-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR RETINAL NEUROPROTECTION | ALLERGAN, INC. (US) | 2013-06-06 | — | — | WO | claimed |
| US-20130137724-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR RETINAL NEUROPROTECTION | ALLERGAN, INC. (US) | 2013-05-30 | — | — | US | claimed |
| US-20130123303-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. (US) | 2013-05-16 | — | — | US | claimed |
| WO-2013070861-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. (US) | 2013-05-16 | — | — | WO | claimed |
| US-20070179182-A1 | 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline | ALLERGAN, INC. | 2007-08-02 | — | — | US | claimed |
| EP-3763370-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE | ALLERGAN, INC. (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-3763370-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE | ALLERGAN, INC. (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-3763370-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE | ALLERGAN, INC. (US) | 2021-01-13 | — | — | EP | disclosed |
| EP-3184110-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE | ALLERGAN INC (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-3184110-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE | ALLERGAN INC (US) | 2020-10-07 | — | — | EP | disclosed |
| EP-3184110-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE | ALLERGAN INC (US) | 2020-10-07 | — | — | EP | disclosed |
| US-10201535-B2 | Pharmaceutical compositions comprising 7-(1H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | ALLERGAN, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-10201535-B2 | Pharmaceutical compositions comprising 7-(1H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | ALLERGAN, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-10201535-B2 | Pharmaceutical compositions comprising 7-(1H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | ALLERGAN, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-10201535-B2 | Pharmaceutical compositions comprising 7-(1H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | ALLERGAN, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| EP-2790673-B1 | OPHTHALMIC COMPOSITIONS COMPRISING POLYVINYL CAPROLACTAM-POLYVINYL ACETATE-POLYETHYLENE GLYCOL GRAFT COPOLYMERS (SOLUPLUS) | ALLERGAN INC (US) | 2017-07-05 | — | — | EP | disclosed |
| US-20170182028-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. | 2017-06-29 | — | — | US | disclosed |
| US-20170182028-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. | 2017-06-29 | — | — | US | disclosed |
| US-20170182028-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. | 2017-06-29 | — | — | US | disclosed |
| US-20170182028-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. | 2017-06-29 | — | — | US | disclosed |
| US-20170182028-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. | 2017-06-29 | — | — | US | disclosed |
| EP-3184110-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE | ALLERGAN, INC. (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-3184110-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE | ALLERGAN, INC. (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-3184110-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE | ALLERGAN, INC. (US) | 2017-06-28 | — | — | EP | disclosed |
| EP-3184110-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE | ALLERGAN, INC. (US) | 2017-06-28 | — | — | EP | disclosed |
| US-20170095466-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. | 2017-04-06 | — | — | US | disclosed |
| US-20170095466-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. | 2017-04-06 | — | — | US | disclosed |
| US-20170095466-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. | 2017-04-06 | — | — | US | disclosed |
| US-20170095466-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. | 2017-04-06 | — | — | US | disclosed |
| US-20170095466-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. | 2017-04-06 | — | — | US | disclosed |
| EP-2776034-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (S)-(+)-7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN INC (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-2776034-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (S)-(+)-7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN INC (US) | 2017-03-22 | — | — | EP | disclosed |
| EP-2776034-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING (S)-(+)-7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN INC (US) | 2017-03-22 | — | — | EP | disclosed |
| US-9579385-B2 | Ophthalmic compositions comprising polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymers | ALLERGAN, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20160151349-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160151349-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160151349-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160151349-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. | 2016-06-02 | — | — | US | disclosed |
| US-20160151349-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. | 2016-06-02 | — | — | US | disclosed |
| US-9308201-B2 | Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | ALLERGAN, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9308201-B2 | Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | ALLERGAN, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9308201-B2 | Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | ALLERGAN, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9308201-B2 | Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | ALLERGAN, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9308201-B2 | Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | ALLERGAN, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| US-9283217-B2 | Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | ALLERGAN, INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-9283217-B2 | Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | ALLERGAN, INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-9283217-B2 | Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | ALLERGAN, INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-9283217-B2 | Pharmaceutical compositions comprising 7-(1 H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | ALLERGAN, INC. (US) | 2016-03-15 | — | — | US | disclosed |
| US-20160051534-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8- TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. | 2016-02-25 | — | — | US | disclosed |
| US-20160051534-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8- TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. | 2016-02-25 | — | — | US | disclosed |
| US-20160051534-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8- TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. | 2016-02-25 | — | — | US | disclosed |
| US-20150231128-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. | 2015-08-20 | — | — | US | disclosed |
| US-20150231128-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. | 2015-08-20 | — | — | US | disclosed |
| US-20150231128-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. | 2015-08-20 | — | — | US | disclosed |
| US-20150231128-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. | 2015-08-20 | — | — | US | disclosed |
| US-20150231128-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. | 2015-08-20 | — | — | US | disclosed |
| CN-104136029-A | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | ALLERGAN INC | 2014-11-05 | — | — | CN | disclosed |
| CN-104136029-A | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | ALLERGAN INC | 2014-11-05 | — | — | CN | disclosed |
| EP-2785345-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR RETINAL NEUROPROTECTION | ALLERGAN, INC. (US) | 2014-10-08 | — | — | EP | disclosed |
| EP-2785345-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR RETINAL NEUROPROTECTION | ALLERGAN, INC. (US) | 2014-10-08 | — | — | EP | disclosed |
| EP-2785345-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR RETINAL NEUROPROTECTION | ALLERGAN, INC. (US) | 2014-10-08 | — | — | EP | disclosed |
| EP-2776034-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. (US) | 2014-09-17 | — | — | EP | disclosed |
| EP-2776034-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. (US) | 2014-09-17 | — | — | EP | disclosed |
| EP-2776034-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. (US) | 2014-09-17 | — | — | EP | disclosed |
| US-20140128329-A1 | OPHTHALMIC COMPOSITIONS COMPRISING POLYVINYL CAPROLACTAM-POLYVINYL ACETATE-POLYETHYLENE GLYCOL GRAFT COPOLYMERS | ALLERGAN, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-20130203809-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203809-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203809-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203809-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203809-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130157963-A1 | OPHTHALMIC COMPOSITIONS COMPRISING POLYVINYL CAPRALACTAM-POLYVINYL ACETATE-POLYETHYLENE GLYCOL GRAFT COPOLYMERS | ALLERGAN, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2013081981-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR RETINAL NEUROPROTECTION | ALLERGAN, INC. (US) | 2013-06-06 | — | — | WO | disclosed |
| WO-2013081981-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR RETINAL NEUROPROTECTION | ALLERGAN, INC. (US) | 2013-06-06 | — | — | WO | disclosed |
| WO-2013081981-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR RETINAL NEUROPROTECTION | ALLERGAN, INC. (US) | 2013-06-06 | — | — | WO | disclosed |
| WO-2013081981-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR RETINAL NEUROPROTECTION | ALLERGAN, INC. (US) | 2013-06-06 | — | — | WO | disclosed |
| US-20130137724-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR RETINAL NEUROPROTECTION | ALLERGAN, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137724-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR RETINAL NEUROPROTECTION | ALLERGAN, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137725-A1 | METHOD OF TREATING SENSORIMOTOR DISORDERS WITH ALPHA-2 ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137725-A1 | METHOD OF TREATING SENSORIMOTOR DISORDERS WITH ALPHA-2 ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137724-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR RETINAL NEUROPROTECTION | ALLERGAN, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137724-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR RETINAL NEUROPROTECTION | ALLERGAN, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137724-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR RETINAL NEUROPROTECTION | ALLERGAN, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| WO-2013070861-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20130123303-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123303-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| WO-2013070861-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20130123303-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123303-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| WO-2013070861-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
| WO-2013070861-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20130123303-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | ALLERGAN, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-7943641-B2 | alpha2 adrenergic receptor agonist; inhibit secretion of epinephrine and norepinephrine; analgesic; chronic neuropathic and visceral pain; treatment of glaucoma or ocular hypertension; side effect reduction (as hypotension and sedation) | ALLERGAN, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-7943641-B2 | alpha2 adrenergic receptor agonist; inhibit secretion of epinephrine and norepinephrine; analgesic; chronic neuropathic and visceral pain; treatment of glaucoma or ocular hypertension; side effect reduction (as hypotension and sedation) | ALLERGAN, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-7943641-B2 | alpha2 adrenergic receptor agonist; inhibit secretion of epinephrine and norepinephrine; analgesic; chronic neuropathic and visceral pain; treatment of glaucoma or ocular hypertension; side effect reduction (as hypotension and sedation) | ALLERGAN, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-7943641-B2 | alpha2 adrenergic receptor agonist; inhibit secretion of epinephrine and norepinephrine; analgesic; chronic neuropathic and visceral pain; treatment of glaucoma or ocular hypertension; side effect reduction (as hypotension and sedation) | ALLERGAN, INC. (US) | 2011-05-17 | — | — | US | disclosed |
| US-20100240699-A1 | METHOD OF TREATING SENSORIMOTOR DISORDERS WITH ALPHA-2 ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. | 2010-09-23 | — | — | US | disclosed |
| US-20100240699-A1 | METHOD OF TREATING SENSORIMOTOR DISORDERS WITH ALPHA-2 ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. | 2010-09-23 | — | — | US | disclosed |
| US-7589057-B2 | Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems | ALLERGAN, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-7589057-B2 | Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems | ALLERGAN, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| WO-2009052073-A2 | METHOD OF TREATING SENSORIMOTOR DISORDERS WITH ALPHA-2 ADRENERGIC RECEPTOR AGONISTS | ALLERGAN, INC. (US) | 2009-04-23 | — | — | WO | disclosed |
| US-20080103175-A1 | alpha2 adrenergic receptor agonist; inhibit secretion of epinephrine and norepinephrine; analgesic; chronic neuropathic and visceral pain; treatment of glaucoma or ocular hypertension; side effect reduction (as hypotension and sedation) | ALLERGAN, INC. | 2008-05-01 | — | — | US | disclosed |
| US-20080103175-A1 | alpha2 adrenergic receptor agonist; inhibit secretion of epinephrine and norepinephrine; analgesic; chronic neuropathic and visceral pain; treatment of glaucoma or ocular hypertension; side effect reduction (as hypotension and sedation) | ALLERGAN, INC. | 2008-05-01 | — | — | US | disclosed |
| US-20080103175-A1 | alpha2 adrenergic receptor agonist; inhibit secretion of epinephrine and norepinephrine; analgesic; chronic neuropathic and visceral pain; treatment of glaucoma or ocular hypertension; side effect reduction (as hypotension and sedation) | ALLERGAN, INC. | 2008-05-01 | — | — | US | disclosed |
| US-20080103175-A1 | alpha2 adrenergic receptor agonist; inhibit secretion of epinephrine and norepinephrine; analgesic; chronic neuropathic and visceral pain; treatment of glaucoma or ocular hypertension; side effect reduction (as hypotension and sedation) | ALLERGAN, INC. | 2008-05-01 | — | — | US | disclosed |
| US-7323477-B2 | 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline | ALLERGAN, INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323477-B2 | 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline | ALLERGAN, INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323477-B2 | 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline | ALLERGAN, INC. (US) | 2008-01-29 | — | — | US | disclosed |
| US-7323477-B2 | 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline | ALLERGAN, INC. (US) | 2008-01-29 | — | — | US | disclosed |
| WO-2007092157-A1 | 7-(1H-IMIDAZOL-4-YL) METHYL) -5,6,7,8-TETRAHYDROQUINOLINE | ALLERGAN, INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| US-20070179182-A1 | 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline | ALLERGAN, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070179182-A1 | 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline | ALLERGAN, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070179182-A1 | 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline | ALLERGAN, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070179182-A1 | 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline | ALLERGAN, INC. | 2007-08-02 | — | — | US | disclosed |
| US-20070179182-A1 | 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline | ALLERGAN, INC. | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070179182-A1 | 7-((1H-imidazol-4-yl)methyl)-5,6,7,8-tetrahydroquinoline | CYP3A7, GOT1, UGT2B7 | CYP19A1 839/4885DRD2 3736/4885DRD3 3386/4885 |
| US-20130157963-A1 | OPHTHALMIC COMPOSITIONS COMPRISING POLYVINYL CAPRALACTAM-POLYVINYL ACETATE-POLYETHYLENE GLYCOL GRAFT COPOLYMERS | PDE6D, UACA, ADCYAP1R1 | CYP19A1 3940/4885DRD2 4670/4885DRD3 4416/4885 |
| US-20160051534-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8- TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | TYR, UGT1A7, IL17A | CYP19A1 1759/4885DRD2 4476/4885DRD3 4250/4885 |
| US-20130123303-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | TYR, UGT1A7, IL17A | CYP19A1 1759/4885DRD2 4476/4885DRD3 4250/4885 |
| US-20170095466-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | TYR, UGT1A7, IL17A | CYP19A1 1759/4885DRD2 4476/4885DRD3 4250/4885 |
| US-20150231128-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | TYR, UGT1A7, IL17A | CYP19A1 1759/4885DRD2 4476/4885DRD3 4250/4885 |
| US-20160151349-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | TYR, UGT1A7, IL17A | CYP19A1 1759/4885DRD2 4476/4885DRD3 4250/4885 |
| US-20170182028-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | TYR, UGT1A7, IL17A | CYP19A1 1759/4885DRD2 4476/4885DRD3 4250/4885 |
| US-20140128329-A1 | OPHTHALMIC COMPOSITIONS COMPRISING POLYVINYL CAPROLACTAM-POLYVINYL ACETATE-POLYETHYLENE GLYCOL GRAFT COPOLYMERS | PDE6D, PDE6C, UACA | CYP19A1 3664/4885DRD2 4535/4885DRD3 4150/4885 |
| US-20100240699-A1 | METHOD OF TREATING SENSORIMOTOR DISORDERS WITH ALPHA-2 ADRENERGIC RECEPTOR AGONISTS | ADRA2A, ADRB2, ADRA2B | CYP19A1 3879/4885DRD2 450/4885DRD3 1261/4885 |
| US-10201535-B2 | Pharmaceutical compositions comprising 7-(1H-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | TYR, UGT1A7, IL17A | CYP19A1 1759/4885DRD2 4476/4885DRD3 4250/4885 |
| US-20130203809-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR TREATING SKIN DISEASES AND CONDITIONS | TYR, UGT1A7, IL17A | CYP19A1 1759/4885DRD2 4476/4885DRD3 4250/4885 |
| US-20080103175-A1 | alpha2 adrenergic receptor agonist; inhibit secretion of epinephrine and norepinephrine; analgesic; chronic neuropathic and visceral pain; treatment of glaucoma or ocular hypertension; side effect reduction (as hypotension and sedation) | ADRB2, ADRA2A, ADRB1 | CYP19A1 2756/4885DRD2 434/4885DRD3 876/4885 |
| US-20130137724-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING 7-(1H-IMIDAZOL-4-YLMETHYL)-5,6,7,8-TETRAHYDRO-QUINOLINE FOR RETINAL NEUROPROTECTION | ALDH1A2, PDE6H, PDE6D | CYP19A1 4768/4885DRD2 832/4885DRD3 933/4885 |
| US-20130137725-A1 | METHOD OF TREATING SENSORIMOTOR DISORDERS WITH ALPHA-2 ADRENERGIC RECEPTOR AGONISTS | ADRA2A, ADRB2, ADRA2B | CYP19A1 3879/4885DRD2 450/4885DRD3 1261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.